Scientific-Technical Areas
Thematic lines
The objective of this line is the development of innovative preclinical and clinical studies for different diseases, with special attention to those affecting the hematopoietic system and the skin, as well as the development of cancer therapies, making their dedication and research highly translational and bridging the gap between basic research and the clinical application of this knowledge.
Genetic and molecular and cellular biology techniques are applied, including the development of animal models of disease, genomic diagnosis of diseases, disease pathophysiology, regenerative medicine based on stem cell therapies, preclinical and clinical cell therapy, and approaches to somatic gene therapy through non-targeted and targeted gene therapy.
-
Cellular Technologies
Aplicaciones Biotecnológicas del RNA Bridge Editing
-
Epithelial Biomedicine
Corrección de mutaciones que causan RDEB y modulación de la hipersensibilidad al dolor y la inflamación mediante la edición de genes in vivo administrada por vectores virales
-
Cellular Technologies
Desarrollando un tratamiento accesible de edición génica para anemias hereditarias
-
Innovative Hematopoietic Therapies
Desarrollo de Medicamentos de terapias avanzadas
-
Biomedical Innovation in Cancer
Descifrando los mecanismos moleculares de la metastasis en cáncer de vejiga para mejorar la terapia
-
Cellular Technologies
Diseño de proteínas basado en IA unido a tecnologías moleculares avanzadas para el desarrollo, investigación y mejora de VLPs de nueva generación para terapias avanzadas
-
Cellular Technologies
Edición génica de AGXT como terapia permanente para pacientes con hiperoxaluria primaria tipo 1
-
Cellular Technologies
Ejecución de proyectos
-
Innovative Hematopoietic Therapies
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application
-
Epithelial Biomedicine
Potenciación de la acción de compuestos con actividad "readthrough" de mutaciones sin sentido en genes causantes de enfermedades raras de piel
-
Innovative Hematopoietic Therapies
Producción de células hematopoyéticas transducidas para los ensayos clínicos Fancolen II y Ladilen.
-
Innovative Hematopoietic Therapies
Red Nacional de Terapias Avanzadas
-
Innovative Hematopoietic Therapies
Revolucionando el tratamiento de la anemia de Fanconi con aproximaciones de terapia génica de precisión ex vivo e in vivo
-
Innovative Hematopoietic Therapies
Revolucionando el tratamiento de la disqueratosis congénita con terapia génica lentiviral y de precisión
-
Innovative Hematopoietic Therapies
Terapias avanzadas de la enfermedad del injerto contra el huésped crónica con células mesenquimales modificadas genéticamente para sobreexpresar CXCR4 e IL10.
-
Biomedical Innovation in Cancer
-
Cellular Technologies
-
Epithelial Biomedicine
-
Innovative Hematopoietic Therapies
-
FORM-022
Flow cytrometry course
-
FORM-041
Basic course on genomic of cancer
-
FORM-042
CARD of mouse reproductive engineering
-
FORM-072
Occupational Risk Prevention Course in Animal Experimentation.
contents set out in Ministerial Order ECC/566/2015, Annex I. Continuous training and maintenance of accreditation of staff of all functions (a-b-c-d-e-f)
-
TERAPINN-001
Mast cell separation
< 50 million
-
TERAPINN-002
Mast cell separation
Between 50 and 100 million
-
TERAPINN-003
Lymphocyte separation
< 50 million
-
TERAPINN-004
Lymphocyte separation
Between 50 and 100 million
-
TERAPINN-005
GFP cell separation. 86uM chamber
-
TERAPINN-006
Separation of Circulating Tumour Cells (CTCs) 1h
1 hour of separation
-
TERAPINN-007
Separation of Circulating Tumour Cells (CTCs) 2h
2 hours of separation
-
TERAPINN-008
Separation of Circulating Tumour Cells (CTCs) 3h
3 hours of separation
-
TERAPINN-009
Separation of Circulating Tumour Cells (CTCs) 4h
4 hours of separation
-
TERAPINN-010
Separation of CD34+ Progenitor Cells - 1h
1-hour separation
-
TERAPINN-011
Separation of CD34+ Progenitor Cells - 2h
2-hour separation
-
TERAPINN-012
Separation of CD34+ Progenitor Cells - 3h
3-hour separation
-
TERAPINN-013
Separation of CD34+ Progenitor Cells - 4h
4-h separation